AZD5004 (ECC5004)
GLP-1 (small molecule) · oral · AstraZeneca (Eccogene)
Summary
- Also known as
- Eccogene → AstraZeneca
- Mechanism
- GLP-1 (small molecule)
- Route
- oral
- Company
- AstraZeneca (Eccogene)
- Highest development stage
- phase 3
- Status (as of data cut)
- Elecoglipron. Phase 2b VISTA (obesity) and SOLSTICE (T2D) positive; phase 3 started (June 2026) verify
- Next milestone
- Phase 3 readouts
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 2b VISTA positive; phase 3 started June 2026 | Phase 3 |
| T2D | 2 phase 3 ongoing | Phase 2b SOLSTICE positive; phase 3 ongoing | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLSTICE (NCT06579105) | 5 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −2.9 % vs −1.7 % Δ −1.2 pp | — | −0.9 vs −0.1 | — | — | — | — | — | — | press release |
| SOLSTICE (NCT06579105) | 15 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −3.4 % vs −1.7 % Δ −1.7 pp | — | −1.1 vs −0.1 | — | — | — | — | — | — | press release |
| SOLSTICE (NCT06579105) | 25 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −4.0 % vs −1.7 % Δ −2.3 pp | — | −1.2 vs −0.1 | — | — | — | — | — | — | press release |
| SOLSTICE (NCT06579105) | 50 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −5.9 % vs −1.7 % Δ −4.2 pp | — | −1.4 vs −0.1 | — | — | — | — | — | — | press release |
| SOLSTICE (NCT06579105) | 75 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −7.7 % vs −1.7 % Δ −6.0 pp | — | −1.9 vs −0.1 | — | — | 37.0 vs 3.0 | 18.0 vs 1.0 | — | — | press release |
| SOLSTICE (NCT06579105) | 75 mg QD (escalated every 4 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −7.0 % vs −1.7 % Δ −5.3 pp | — | −1.6 vs −0.1 | — | — | — | — | — | — | press release |
| VISTA (NCT06579092) | 5 mg QD | obesity | 36 | 310 | −2.7 % vs −0.6 % Δ −2.1 pp | — | — | — | — | — | — | — | — | press release |
| VISTA (NCT06579092) | 15 mg QD | obesity | 36 | 310 | −6.5 % vs −0.6 % Δ −5.9 pp | — | — | — | — | — | — | — | — | press release |
| VISTA (NCT06579092) | 50 mg QD (escalated every 4 weeks) | obesity | 36 | 310 | −9.2 % vs −0.6 % Δ −8.6 pp | — | — | — | — | — | — | — | — | press release |
| VISTA (NCT06579092) | 75 mg QD (escalated weekly) | obesity | 36 | 310 | −11.8 % vs −0.6 % Δ −11.2 pp | — | — | — | — | — | — | — | — | press release |
| VISTA (NCT06579092) | 75 mg QD (escalated every 2 weeks) | obesity | 36 | 310 | −11.1 % vs −0.6 % Δ −10.5 pp | — | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 75 mg QD (escalated every 2 weeks): GI events from the release, which reports them for «elecoglipron 75 mg» (matched to this arm by its HbA1c and weight).
Verbatim quotes from the source (19)
- 5 mg QD · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 15 mg QD · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 50 mg QD (escalated every 4 weeks) · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 75 mg QD (escalated weekly) · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 75 mg QD (escalated every 2 weeks) · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 5 mg QD · hba1c · publication (abstract)
change from baseline in HbA1c ranged between -0·91% (95% CI -1·25 to -0·58; 5 mg elecoglipron)
- 5 mg QD · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 15 mg QD · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 15 mg QD · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 25 mg QD · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 25 mg QD · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 50 mg QD (escalated every 2 weeks) · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 50 mg QD (escalated every 2 weeks) · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 75 mg QD (escalated every 2 weeks) · hba1c · publication (abstract)
-1·88% (-2·23 to -1·53; 75 mg elecoglipron with every 2-week dose-escalation step) compared with -0·15% (-0·42 to 0·12) with placebo
- 75 mg QD (escalated every 2 weeks) · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 75 mg QD (escalated every 2 weeks) · nausea · press release, safety paragraph (SOLSTICE)
In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
- 75 mg QD (escalated every 2 weeks) · vomiting · press release, safety paragraph (SOLSTICE)
In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
- 75 mg QD (escalated every 4 weeks) · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 75 mg QD (escalated every 4 weeks) · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
Registered trials (9)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| Elevate-CKD A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | CKD | Phase 3 | recruiting | 2026-08 → 2030-10 | 7000 | recruiting | NCT07753993 |
| Elevate-HF A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | CV outcomes | Phase 3 | recruiting | 2026-08 → 2029-09 | 6950 | recruiting | NCT07761117 |
| Elecoglipron A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus | Obesity | Phase 3 | recruiting | 2026-08 → 2028-04 | 351 | recruiting | NCT07775404 |
| Eluminate-1 A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus | T2D | Phase 3 | recruiting | 2026-07 → 2028-07 | 800 | recruiting | NCT07662044 |
| Eluminate-5 A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus | T2D | Phase 3 | recruiting | 2026-07 → 2028-07 | 2000 | recruiting | NCT07662109 |
| Eluminate-4 A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin | T2D | Phase 3 | recruiting | 2026-07 → 2028-07 | 900 | recruiting | NCT07662135 |
| Eluminate-2 A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | T2D | Phase 3 | recruiting | 2026-07 → 2028-05 | 1200 | recruiting | NCT07662213 |
| Eluminate-3 A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin | T2D | Phase 3 | recruiting | 2026-07 → 2028-05 | 600 | recruiting | NCT07664553 |
| Embold A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM | Obesity | Phase 3 | recruiting | 2026-06 → 2028-07 | 4500 | recruiting | NCT07667803 |
Primary sources
- AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08. Available from: https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385
- Aroda VR, Davies MJ, Maaske J, Millegård M, Juan VL, Aberle J, et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial. Lancet. 2026;407(10547):2515-2527. PMID: 42259343.
How to cite this page
Cite the primary publication for any single result; every value above links to it.